March 23, 2017

HealthCap’s 39th IPO as HealthCap V company MIPS AB completes IPO on Nasdaq OMX Stockholm

MIPS AB has successfully completed its Initial Public Offering on Nasdaq OMX Stockholm’s main market. Trading started today under the ticker MIPS.   Source: MIPS
March 23, 2017

Targovax ASA moves share listing to Oslo Børs

Published: 07:00 CET 23-03-2017 /GlobeNewswire /Source: Targovax ASA / : TRVX /ISIN: NO0010689326 Targovax ASA moves share listing to Oslo Børs   Oslo, Norway, 23 M...
Read more
March 22, 2017

BioClin Therapeutics, Inc., Raises $30 Million in Series B Financing Led by Sofinnova Ventures and Ysios Capital

BioClin Therapeutics, Inc., a privately-held clinical stage drug development company developing a first-in-class anti-FGFR3 (fibroblast growth factor receptor 3) monoclonal antibod...
Read more
March 22, 2017

Nexstim Plc Signs an Independent Selling Representative Agreement in the U.S. with JTec Surgical, Inc.

Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company"), a medical technology company with a pioneering navigated non-invasive brain stimulation system, announces that its whol...
Read more
March 22, 2017

Aprea Therapeutics Announces Research Collaboration with Memorial Sloan Kettering Cancer Center

March 22, 2017—BOSTON, MA., and STOCKHOLM, SWEDEN, March 22, 2017 – Aprea Therapeutics, a privately held, clinical stage biopharmaceutical company developing novel anticancer t...
Read more
March 17, 2017

Targovax ASA applies for transfer to Oslo Stock Exchange main list

7.March 2017 at 12:10:23 CET The board of directors of Targovax ASA has resolved to send an application to transfer the listing of the company's shares from Oslo Axess to Oslo S...
Read more
March 17, 2017

Cerenis Therapeutics announces that CARAT Phase 2 Study data on CER-001 have been presented at ACC annual meeting 2017

Cerenis Therapeutics announces that CARAT Phase 2 Study data on CER-001 have been presented at ACC annual meeting 2017   Primary endpoint, regression of coronary...
Read more
March 17, 2017

Nordic Nanovector announces first patient dosed in Phase 1 study of Betalutin® in diffuse large B-cell lymphoma (DLBCL), an aggressive form of NHL

Oslo, Norway, 17 March 2017 Nordic Nanovector ASA (OSE: NANO) announces that the first patient has been dosed in its Phase 1 study evaluating Betalutin® (177Lu-satetraxetan-lil...
Read more
March 15, 2017

Targovax ASA: Annual Report 2016

15.March 2017 at 21:15:53 CET On 15 March 2017, the Board of Directors of Targovax ASA approved the financial statements for 2016 for issuance, subject to approval by the Annual...
Read more
March 14, 2017

Strongbridge Biopharma plc to Present at the 27th Annual Oppenheimer Healthcare Conference and the 16th Annual Needham Healthcare Conference

DUBLIN, Ireland and TREVOSE, Pa., March 14, 2017 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq:SBBP), a global commercial-stage biopharmaceutical company focu...
Read more